Moneyview Ltd's Q2 FY27 numbers came in strong, with revenue of Rs. 1,120.18 Cr (+41.04% YoY) and PAT growth of +418.36% YoY. Here's a quick read of what worked, what to watch, and what management said.
| Results date | November 05, 2026 |
|---|---|
| Revenue (Q2) | Rs. 1,120.18 Cr (+41.04% YoY) |
| PAT (Q2) | Rs. 200.72 Cr (+418.36% YoY) |
| EPS (Q2) | Rs. 1.35 |
Moneyview delivered 41.04% YoY revenue growth with normalized PAT up 169.05% and pre-provision margin expanding 666 bps to 49.60%, aided by a 472 bps YoY improvement in the credit-cost proxy. The Rs.750 crore IPO and CCPS conversion cut gearing from 2.32x to 1.67x, though consolidated H1 CFO remained negative at Rs.79.66 crore, keeping the model dependent on borrowings and fresh equity. No prior management guidance exists in the record, so no beat can be scored; the Rs.250 crore WFPL infusion and unutilized IPO proceeds are post-quarter deployment catalysts to watch.
| Driver | What happened | Verdict |
|---|---|---|
| Revenue "ahead — sector tailwind" ("NBFC retail loan growth accelerated to 21.4% YoY in July") | Revenue from operations +41.04% YoY, +7.59% QoQ | Played out |
| "Spread likely compressing at the margin" — funding headwind "builds from Q3 onward" | Finance cost/revenue fell to 17.36% from 19.45% YoY; net portfolio interest +33.30% H1, matching income growth — this quarter); the post-quarter 25 bps repo hike to 5.50% per pre-call note (web-sourced, dated) may still… | Contradicted |
| Provisions tailwind from improving unsecured delinquencies, low-ticket business-loan stress to probe | Impairment/revenue 25.57% vs 30.29% YoY; impairment +19.08% YoY vs revenue +41.04% | Played out |
| Watch: clarify standalone-vs-consolidated bridge and WFPL's Rs.1,517.49 crore FY26 turnover basis | Both statements provided; the turnover basis remains unreconciled (consolidated FY26 revenue was Rs.3,351.16 crore) | Partially |
| Watch: Rs.250 cr infusion deployment (post-quarter) | IPO proceeds unutilized at Sep 30; infusion outside Q2 balances — as pre-noted — remains open for the call | Not observable in Q2 |
| Watch: first NBFC KPI set (AUM, GNPA, CRAR, spreads) | None disclosed in the filing — remains open for the November 5 call | Not observable |
| What management said | Where | What happened | Verdict |
|---|---|---|---|
| "Augment WFPL's capital base and enable it to expand its lending operations" (Rs.250 cr infusion) | Exchange filing of October 15, 2026 (pre-call record) | Loan book +8.17% in H1 to Rs.5,741.19 crore — but the infusion landed 15 days after quarter close and proceeds were unutilized at Sep 30 | Too Early |
| IPO proceeds per stated objects | IPO deviation statement filed with results | Nil utilisation, no deviation reported for the quarter — nil use, as disclosed | Confirmed |
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.